A Product and Pipeline Analysis of the Antibacterial Drugs Market

Regulatory Approaches to Combat Microbial Resistance and Stimulate Antibiotics R&D

USD 3,950

* Required Fields

USD 3,950

PAY BY INVOICE

Be the first to review this product

Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) market, with particular focus on the antibiotics currently under development. A list of currently available and marketed antibacterial drugs under the approved antibacterial drug classes has been provided. Product and pipeline assessment for recently approved antibacterial drugs, antibacterials under FDA review, as well as phase 3 antibacterial drug candidates have been provided. A detailed overview of the various regulatory approaches to foster innovation in the development of new antibiotics has been provided as well.

Table of Contents

Executive SummaryExecutive Summary—Key FindingsExecutive Summary—Key Findings (continued)Executive Summary—Key Findings (continued)Antibacterial Drugs Market—Game-changing StrategiesKey Merger, Acquisition, and Partnership AssessmentKey Merger, Acquisition, and Partnership Assessment (continued)Key Merger, Acquisition, and Partnership Assessment (continued)Key Merger, Acquisition, and Partnership Assessment (continued)Key Merger, Acquisition, and Partnership Assessment (continued)Methodology and ScopeIntroductionIntroduction Introduction (continued) Market Overview—SegmentationClassification of Antibacterial Drugs by Mechanism of ActionAntibacterial Drugs—Approved and Novel Product Classes Synopsis Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued) Dosing Regimen of Commonly Prescribed AntigensDosing Regimen of Commonly Prescribed Antigens (continued)Dosing Regimen of Commonly Prescribed Antigens (continued)Dosing Regimen of Commonly Prescribed Antigens (continued)Dosing Regimen of Commonly Prescribed Antigens (continued)Dosing Regimen of Commonly Prescribed Antigens (continued)Dosing Regimen of Commonly Prescribed Antigens (continued)Dosing Regimen of Commonly Prescribed Antigens (continued)Dosing Regimen of Commonly Prescribed Antigens (continued)Dosing Regimen of Commonly Prescribed Antigens (continued)Dosing Regimen of Commonly Prescribed Antigens (continued)Dosing Regimen of Commonly Prescribed Antigens (continued)Dosing Regimen of Commonly Prescribed Antigens (continued)Dosing Regimen of Commonly Prescribed Antigens (continued)Antibacterial Drugs Market—Pipeline AnalysisAntibacterial Drugs—Competitive Landscape of Products in DevelopmentAntibacterial Drugs—Pipeline AnalysisAntibacterial Drugs—Pipeline SynopsisAntibacterial Drugs—Pipeline Synopsis (continued)Antibacterial Drugs—Pipeline Synopsis (continued)Antibacterial Drugs—Pipeline Synopsis (continued)Antibacterial Drugs—Pipeline Synopsis (continued)Antibacterial Drugs—Pipeline Synopsis (continued)Antibacterial Drugs—Pipeline Synopsis (continued)Antibacterial Drugs—Pipeline Synopsis (continued)Antibacterial Drugs—Pipeline Synopsis (continued)Antibacterial Drugs—Pipeline Synopsis (continued)Antibacterial Drugs—Pipeline Synopsis (continued)Antibacterial Drugs Market—Major Clinical MilestonesAntibacterial Drugs Market—Major Ongoing/Recently Completed Clinical Trials Antibacterial Drugs Market—Major Ongoing/Recently Completed Clinical Trials (continued)Antibacterial Drugs Market—Major Ongoing/Recently Completed Clinical Trials (continued)Antibacterial Drugs Market—Product Dashboard of Recently Approved and Late-stage Pipeline Drug CandidatesTedizolid Phosphate—Cubist PharmaceuticalsDalbavancin (Dalvance™)—Durata TherapeuticsCeftolozane + Tazobactam—Cubist PharmaceuticalsOritavancin (Orbactiv™)—The Medicines CompanyCeftazidime + Avibactam (CAZ-AVI)—AstraZenecaCadazolid—Actelion PharmaceuticalsCarbavance—Rempex Pharmaceuticals (The Medicines Company)Delafloxacin—Melinta Therapeutics Eravacycline—Tetraphase Pharmaceuticals Plazomicin—AchaogenSolithromycin—Cempra PharmaceuticalsSurotomycin—Cubist PharmaceuticalsAntibiotic Resistance—A Critical Unmet Need that Poses Challenges to Antibiotic R&DCommon Mechanisms of Antibiotic ResistanceKey Challenges to Antibiotic Research & DevelopmentHard-to-treat Pathogens/Superbugs That Pose a Serious Threat to Drug MakersNew Antibiotics in the Pipeline That Help Overcome Drug ResistanceNew Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)Antibacterial Drugs Market—Timeline of Key EventsAntibacterial Drug Classes—FDA Approval TimelineAntibacterial Drug Classes—FDA Approval Timeline (continued)Antibacterial Drugs—FDA Approval Timeline Antibacterial Drugs Market—Timeline of Key EventsAntibacterial Drugs Market—Timeline of Key Events (continued)Regulatory Approaches to Stimulate Antibiotics R&DRegulatory Policies to Stimulate Antibiotics R&DGenerating Antibiotics Incentives Now (GAIN) Act Implementation of the (GAIN) Act Antibiotic Development to Advance Patient Treatment Act (ADAPT): H.R. 3742 IDSA’s 10 x ‘20 InitiativeAdditional Economic Incentives—Tax Credits Additional Economic Incentives—Federal Research FundingAdditional Economic Incentives—Federal Research Funding (continued)Additional Economic Incentives—Federal Research Funding (continued)PPPs—The European EffortPPPs—The European Effort (continued)PPPs—BARDAPPPs—BARDA (continued)Antibacterial Drugs Market—Key Companies to Watch Key Companies to WatchKey Companies to Watch (continued)ConclusionsConclusions and RecommendationsLegal DisclaimerAppendixList of AbbreviationsThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue PropositionGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Related Research

Release Date : 18-Sep-17

Region : North America

Release Date : 18-Sep-17

Region : North America

Release Date : 18-Sep-17

Region : North America

Release Date : 15-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.